Effect of Dipeptidyl Peptidase-4 Inhibitors on the Risk of Bone Fractures in a Korean Population

다국어 초록 (Multilingual Abstract)

Background: There have been equivocal results in studies of the effects of dipeptidyl peptidase-4 inhibitors (DPP-4i) on fractures. In this study, we analyzed the effect of DPP-4i on bone fracture risk in a Korean population.
Methods: We extracted subjects (n = 11,164) aged 50 years or older from the National Health Insurance Service–National Sample Cohort 2.0 from 2009 to 2014. Our control group included subjects without diabetes (n = 5,582), and our treatment groups with diabetes included DPP-4i users (n = 1,410) and DPP-4i non-users (n = 4,172). The primary endpoint was the incidence of a composite outcome consisting of osteoporosis diagnosis, osteoporotic fractures, vertebral fractures, non-vertebral fractures, and femoral fractures. The secondary endpoint was the incidence of each individual component of the composite outcome. Survival analysis was performed with adjustment for age, gender, diabetes complications severity index, Charlson comorbidity index, hypertension medication, and dyslipidemia treatment.
Results: The incidence of the composite outcome per 1,000 person-years was 0.089 in DPP-4i users, 0.099 in DPP-4i non-users, and 0.095 in controls. There was no significant difference in fracture risk between DPP-4i users and DPP-4i non-users or controls after the adjustments (P > 0.05). The incidences of osteoporosis diagnosis, osteoporotic fractures, vertebral fractures, non-vertebral fractures, and femoral fractures were not significantly different between DPP-4i users and non-users. The results of subgroup analyses by gender and age were consistent.
Conclusion: DPP-4i had no significant effect on the risk of fractures in a Korean population.

참고문헌 (Reference)

1 Schwartz AV, "Thiazolidinedione use and bone loss in older diabetic adults" 91 (91): 3349-3354, 2006

2 Gamble JM, "The risk of fragility fractures in new users of dipeptidyl peptidase-4 inhibitors compared to sulfonylureas and other anti-diabetic drugs : a cohort study" 136 : 159-167, 2018

3 Choi HJ, "Risk of fractures and diabetes medications : a nationwide cohort study" 27 (27): 2709-2715, 2016

4 Kunutsor SK, "Renin-angiotensin system inhibitors and risk of fractures: a prospective cohort study and meta-analysis of published observational cohort studies" 32 (32): 947-959, 2017

5 Kanazawa I, "Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus" 28 (28): 554-560, 2010

6 Bonnet N, "Protective effect of beta blockers in postmenopausal women : influence on fractures, bone density, micro and macroarchitecture" 40 (40): 1209-1216, 2007

7 Montagnani A, "Osteoporosis and risk of fracture in patients with diabetes : an update" 23 (23): 84-90, 2011

8 Bollag RJ, "Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors" 141 (141): 1228-1235, 2000

9 Schwartz AV, "Older women with diabetes have a higher risk of falls : a prospective study" 25 (25): 1749-1754, 2002

10 Mai QG, "Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats" 112 (112): 2902-2909, 2011

11 Rosolová H, "Macrovascular and microvascular complications in type 2 diabetes patients" 54 (54): 229-237, 2008

12 Wallace C, "Incidence of falls, risk factors for falls, and fall-related fractures in individuals with diabetes and a prior foot ulcer" 25 (25): 1983-1986, 2002

13 International Diabetes Federation, "IDF Diabetes Atlas"

14 Reid IR, "Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women : a randomized controlled trial" 109 (109): 362-370, 2000

15 de Groot V, "How to measure comorbidity. a critical review of available methods" 56 (56): 221-229, 2003

16 Wong IP, "Gastrointestinal peptides and bone health" 17 (17): 44-50, 2010

17 Henriksen DB, "Four-month treatment with GLP-2 significantly increases hip BMD : a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD" 45 (45): 833-842, 2009

18 Wang Z, "Effects of statins on bone mineral density and fracture risk: a PRISMA-compliant systematic review and meta-analysis" 95 (95): e3042-, 2016

19 Tang SY, "Effects of non-enzymatic glycation on cancellous bone fragility" 40 (40): 1144-1151, 2007

20 Henriksen DB, "Disassociation of bone resorption and formation by GLP-2 : a 14-day study in healthy postmenopausal women" 40 (40): 723-729, 2007

21 Fu J, "Dipeptidyl peptidase-4 inhibitors and fracture risk : an updated meta-analysis of randomized clinical trials" 6 (6): 29104-, 2016

22 Monami M, "Dipeptidyl peptidase-4 inhibitors and bone fractures : a meta-analysis of randomized clinical trials" 34 (34): 2474-2476, 2011

23 Schwartz AV, "Diabetes, fracture, and bone fragility" 5 (5): 105-111, 2007

24 Glasheen WP, "Diabetes complications severity index(DCSI)-update and ICD-10 translation" 31 (31): 1007-1013, 2017

25 이용호, "Data Analytic Process of a Nationwide Population-Based Study Using National Health Information Database Established by National Health Insurance Service" 대한당뇨병학회 40 (40): 79-82, 2016

26 Röhrborn D, "DPP4 in diabetes" 6 : 386-, 2015

27 Fehmann HC, "Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide" 16 (16): 390-410, 1995

28 Isidro ML, "Bone disease in diabetes" 6 (6): 144-155, 2010

29 Johnston SS, "Association between hypoglycaemic events and fall-related fractures in Medicare-covered patients with type 2 diabetes" 14 (14): 634-643, 2012

30 Dacquin R, "Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo" 164 (164): 509-514, 2004

31 Zaidi M, "Amylin in bone conservation current evidence and hypothetical considerations" 4 (4): 255-259, 1993

32 Okazaki K, "Advanced glycation end products(AGEs), but not high glucose, inhibit the osteoblastic differentiation of mouse stromal ST2 cells through the suppression of osterix expression, and inhibit cell growth and increasing cell apoptosis" 91 (91): 286-296, 2012